Sweden (SE)

Value of Tumor Growth Rate (TGR) as an Early Predictor of Patients' Outcome in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs): The GREPONET Study (2018) Lamarca A, Crona J, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Najran P, et al. Conference contribution Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome (2018) Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel ME, Valle JW, Caplin ME, et al. Journal article Time to Sustained Improvement in Bowel Movement Frequency With Telotristat Ethyl: Analysis of the Phase 3 TELESTAR Study (2018) Dillon JS, Kulke MH, Pavel ME, Horsch D, Anthony LB, Warner RRP, Bergsland E, et al. Conference contribution Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Two Phase 3 Studies in Carcinoid Syndrome (2018) Dillon J, Kulke M, Warner R, Bergsland E, Welin S, O'Dorisio T, Mckee C, et al. Conference contribution Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis (2018) Iacobaeus E, Douagi I, Jitschin R, Marcusson-Stahl M, Andren AT, Gavin C, Lefsihane K, et al. Journal article Conodont biostratigraphy and carbon isotope stratigraphy of the middle Ordovician (Darriwilian) Komstad Limestone Formation, southern Sweden (2018) Wu R, Calner M, Lehnert O, Lindskog A, Erlström M, Joachimski M Journal article SECUKINUMAB EFFICACY IN PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE - POOLED ANALYSIS FROM TWO PHASE-III TRIALS OVER 2 YEARS (2018) Wallman JK, Schett G, Mcinnes IB, Quebe-Fehling E, Rasouliyan L, Pricop L, Fasth AE, Gaillez C Conference contribution NEW SYSTEMIC SCLEROSIS RISK LOCI IDENTIFIED THROUGH A META-GWAS STRATEGY (2018) Lopez-Isac E, Acosta-Herrera M, Assassi S, Simeon CP, Carreira PE, Castellvi I, Ortego-Centeno N, et al. Conference contribution Impact of secukinumab treatment on psoriatic arthritis patients with or without enthesitis at baseline: pooled data from two phase 3 studies (FUTURE 2 and FUTURE 3) (2018) Wallman JK, Schett G, Mcinnes IB, Quebe-Fehling E, Rasouliyan L, Pricop L, Gaillez C, Fasth AE Conference contribution The involvement of Toll-like receptor 9 in the pathogenesis of erosive autoimmune arthritis (2018) Fischer A, Abdollahi-Roodsaz S, Boehm C, Niederreiter B, Meyer B, Yau ACY, Lonnblom E, et al. Journal article